Meritage Portfolio Management Sells 1,361 Shares of Gilead Sciences, Inc. $GILD

Meritage Portfolio Management lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,919 shares of the biopharmaceutical company’s stock after selling 1,361 shares during the period. Meritage Portfolio Management’s holdings in Gilead Sciences were worth $5,645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $25,000. Activest Wealth Management raised its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $29,000. Colonial Trust Advisors raised its stake in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares in the last quarter. Finally, Core Alternative Capital raised its stake in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 241 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $117.18 on Friday. The firm has a market cap of $145.40 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 0.80 and a beta of 0.34. The company’s 50 day moving average is $114.65 and its 200 day moving average is $110.26. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52-week low of $84.17 and a 52-week high of $121.83.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is currently 62.95%.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,402,130 over the last three months. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research note on Wednesday. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Finally, Cantor Fitzgerald lifted their price target on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $118.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.